PYC Therapeutics Limited

As of June 30, 2026, PYC THERAPEUTICS LTD. carries a market capitalization of 1.12B, placing it among publicly traded companies globally. Its enterprise value stands at 806.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PYC THERAPEUTICS LTD.'s next confirmed earnings release is scheduled for March 1, 2027.

As of June 30, 2026, PYC THERAPEUTICS LTD. has 983.51M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, PYC THERAPEUTICS LTD. maintains a current ratio of 33.48, meaning it holds 33.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.09, indicating conservative leverage, while an interest coverage ratio of -2,028.34 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, PYC THERAPEUTICS LTD. posted a negative return on equity (ROE) of -10.05, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.72, reflecting losses generated across the asset base.

As of the close on October 22, 2026, PYC THERAPEUTICS LTD.'s stock has gained approximately 53.08% over the past 52 weeks.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -56.79M, while operating income came in at -57.21M.

As of June 30, 2026, PYC THERAPEUTICS LTD. holds 309.73M in cash and equivalents against 432,517.65 in total debt, resulting in a net debt position of -37.07M. Total book value stands at 479.81M, with working capital of 323.76M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -34.92, meaning PYC THERAPEUTICS LTD. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

PYC THERAPEUTICS LTD.'s most recent stock split took place on February 4, 2026.